-+ 0.00%
-+ 0.00%
-+ 0.00%
On November 17, Luye Pharmaceutical Group announced that LY03021, the next-generation central nervous system drug under development independently developed by the company, has obtained permission from the US Food and Drug Administration to conduct clinical trials and is intended to be used to treat depression.
Share
Listen to the news
On November 17, Luye Pharmaceutical Group announced that LY03021, the next-generation central nervous system drug under development independently developed by the company, has obtained permission from the US Food and Drug Administration to conduct clinical trials and is intended to be used to treat depression.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending